A Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25.
Latest CG Oncology news
We have not published a story on CG Oncology yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $19.6 million, plus short-term investments of $1.01 billion, $1.03 billion in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about CG Oncology
What is the ticker symbol of CG Oncology?
CG Oncology, Inc. trades under the ticker CGON on NASDAQ.
Where is CG Oncology listed?
CG Oncology, Inc. is listed on NASDAQ.
What is the SEC CIK of CG Oncology?
The SEC Central Index Key (CIK) for CG Oncology, Inc. is 1991792. Its filings are on SEC EDGAR.
How many shares does CG Oncology have outstanding?
88,640,375 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is CG Oncology listed under?
Our directory records CG Oncology, Inc. under United States.
What does CG Oncology do?
Our directory classifies CG Oncology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of CG Oncology?
The ISIN recorded for CG Oncology, Inc. is US1569441009.
Does aibio.space cover CG Oncology?
aibio.space lists CG Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is CG Oncology incorporated?
SEC records list its state or country of incorporation as DE.
Is CG Oncology profitable?
CG Oncology, Inc. reported a net loss of $161.0 million for the fiscal year ended Dec 31, 2025, and used $132.3 million of cash in operations, per its annual report to the SEC.
How much does CG Oncology spend on research and development?
$116.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does CG Oncology have?
$1.03 billion in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is CG Oncology's market cap?
We do not publish live share prices. In its annual report, CG Oncology, Inc. put the market value of shares held by non-affiliates (public float) at $1.70 billion as of Jun 30, 2025.
Is CG Oncology a smaller reporting company?
SEC records list CG Oncology, Inc.'s filer category as: Large accelerated filer.
Where is CG Oncology headquartered?
SEC records list its business address as 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247.
Investor discussion: CG Oncology
Members talk about CG Oncology (CGON). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at CG Oncology, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CGON on TradingView.
SEC filings and registration
SEC name
CG Oncology, Inc.
CIK
1991792
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
CGON (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Phone
(949) 409-3700
Shares outstanding
88,640,375 as of 2026-08-05 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
CG Oncology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CGON, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio